Oral Cancer News | Tag Archive

Presence of rash associated with improved survival in patients receiving adjuvant Erbitux® for locally advanced head and neck cancer

Tuesday, November 17, 2009

Source: professional.cancerconsultants.com Author: staff A multicenter randomized trial has shown that patients with locoregionally advanced head and neck cancer receiving adjuvant Erbitux® (cetuximab) and radiotherapy who develop a rash have a better survival than patients receiving this therapy who don’t develop a rash. The details of this five-year follow-up of a Phase III randomized study [...]

Erbitux recognized by ASCO as a 2009 major cancer advance as first SCCHN treatment to improve survival in 30 years

Monday, November 16, 2009

0 Comments

Source: www.vwd.de Author: press release The American Society of Clinical Oncology (ASCO) has once again recognized Erbitux® (cetuximab) as one of the major clinical cancer advances of 2009. This year Erbitux was selected by ASCO for providing the first significant increase in survival for 30 years in the treatment of patients with first-line recurrent and/or [...]

Report highlights cancer advances

Tuesday, November 10, 2009

0 Comments

Source: www.medpagetoday.com Author: Charles Bankhead, Staff Writer, MedPage Today As the war on cancer enters its fifth decade, 51 studies stood out as examples of progress that occurred in the past year, as determined by the American Society of Clinical Oncology (ASCO) and reported in “Clinical Cancer Advances 2009.” Reflecting input from specialists throughout the [...]

At our throats

Thursday, October 15, 2009

0 Comments

Source: www.forbes.com Author: Matthew Herper Oncologist Maura Gillison was looking for patients with tonsil cancer for a clinical study several years ago. The first enlisted was a malpractice lawyer, followed by a doctor, then a scientist. She joked to a colleague that all she needed was a rear admiral. In walked a member of the [...]

Erbitux® may improve treatment of squamous cell carcinoma of the esophagus

Saturday, October 3, 2009

0 Comments

Source: professional.cancerconsultants.com Author: staff Researchers from Germany have reported that Erbitux® (cetuximab) improves response rate, time to disease progression, and overall survival of patients with metastatic squamous cell carcinoma receiving Platinol® (cisplatin) and 5-FU. The details of this study appeared in the October 2009 issue of Annals of Oncology.[1] Esophageal cancer is relatively common and [...]

Lilly Erbitux cancer drug not worth price, U.S. scientists say

Sunday, September 27, 2009

0 Comments

Source: www.bloomberg.com Author: Lisa Rapaport Eli Lilly & Co.’s tumor-fighter Erbitux doesn’t prolong lung cancer patients’ lives enough to justify its $80,000 cost, U.S. scientists said in commentary published today. Erbitux added to other cancer drugs extends survival about 1.2 months more than chemotherapy alone, making the price too high for a “marginal benefit,” commentary [...]

Initial COIN study results presented at European Oncology Congress

Thursday, September 24, 2009

0 Comments

Source: Drugs.com Author: Staff • Results inconsistent with data from all Erbitux pivotal studies • Further analyses planned by the Medical Research Council that conducted the independent COIN study Berlin/Darmstadt, Germany, September 23, 2009 – The Medical Research Council (MRC), a UK-based, publicly-funded organization dedicated to improving human health, today presented the initial results of [...]

U.S. scientists say Lilly Erbitux cancer drug not worth price

Tuesday, June 30, 2009

0 Comments

Source: Bloomberg Author: Lisa Rapaport Eli Lilly & Co.’s tumor-fighter Erbitux doesn’t prolong lung cancer patients’ lives enough to justify its $80,000 cost, U.S. scientists said in commentary published today. Erbitux added to other cancer drugs extends survival about 1.2 months more than chemotherapy alone, making the price too high for a “marginal benefit,” commentary [...]

Use of Erbitux in head and neck cancer rejected by NICE

Thursday, June 25, 2009

0 Comments

Source: Pharmafocus.com Author: Staff Erbitux has failed to win NICE approval for the treatment of head and neck cancer, due to doubts over its cost and clinical effectiveness compared to existing treatments. It was rejected under NICE’s new scheme to make more end-of-life drugs available by extending the threshold at which they are considered cost-effective, [...]

Monoclonal Antibody Drugs for Cancer Treatment

Sunday, April 5, 2009

0 Comments

Source: www.newswise.com Author: staff The strategy of using monoclonal antibodies for cancer treatment was first described in the late 1970s with the promise that they could be developed into therapies that were highly specific to cancer cells, killing them with few or no side effects. For several types of cancer, monoclonal antibodies have already offered [...]

Tag Archive | "erbitux"